ScienceDaily: From DNA to Diagnosis: Integrating Genome Data into Patient Care
The USTAR Center for Genetic Discovery is partnering with California-based Omicia, Inc., to make analyzing a patient’s genome as routine as performing a blood test.
The USTAR Center for Genetic Discovery is partnering with California-based Omicia, Inc., to make analyzing a patient’s genome as routine as performing a blood test.
Martin Reese, co-founder and President of Omicia, Inc., explains how making tools to simplify genetic analysis reports will increase the clinical applications of human genome sequencing over the next 3-5 years.
Omicia plans to use the proceeds from a recent $6.8 million Series A financing to continue developing an informatics workflow that would help diagnostic laboratories develop and launch genomics-based tests.
Omicia, Inc., an analytical genome interpretation company, announced today it has closed $6.8 million of Series A financing to expand its marketing reach and further optimize its big data genomics offerings.
Omicia has picked up a $6.8 million Series A led by Artis Ventures. Other investors include Buchanan Investments and Bay City Capital.
Omicia and the University of Utah said this week that they have signed a two-year licensing agreement that allows researchers involved in the Utah Genome Project use Opal, Omicia’s platform for analyzing genomics in research and clinical applications, to analyze disease-causing variants.
Under a two-year licensing agreement with Omicia, the University of Utah’s Utah Genome Project will use and advance Opal, the company’s whole genome analysis platform for research and clinical applications.
A team of clinicians and researchers used whole-genome sequencing to uncover variants possibly linked to a patient’s obsessive-compulsive disorder.
Genome sequencing is starting to deliver a medical revolution for families with rare diseases. The benefits may one day come to us all.
The University of Utah Health Sciences has formally launched a Genome Board—an interdisciplinary, clinical rounds system that processes complex genetic information into actionable clinical knowledge. Included in the analysis procedure is a software tool called Opal, developed by Omicia, Inc.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
You can adjust all of your cookie settings using the tabs to the left.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
More information about our Cookie Policy
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
You can adjust all of your cookie settings using the tabs to the left.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
More information about our Cookie Policy